This is a sophisticated healthcare M&A case that tests valuation, synergy identification, and deal structuring. The case cleverly reveals that the initial deal appears poor on a standalone basis (7% ROI < 13% WACC), but becomes attractive through operational improvements and revenue synergies. The critical tension involves managing physician incentives post-acquisition to prevent key talent erosion.